Trevena, Inc. (TRVN) Position Increased by Bourgeon Capital Management LLC
Bourgeon Capital Management LLC boosted its stake in shares of Trevena, Inc. (NASDAQ:TRVN) by 56.8% during the second quarter, Holdings Channel reports. The firm owned 53,031 shares of the biopharmaceutical company’s stock after buying an additional 19,200 shares during the period. Bourgeon Capital Management LLC’s holdings in Trevena were worth $122,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. American International Group Inc. increased its stake in shares of Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 1,816 shares during the period. Daiwa SB Investments Ltd. purchased a new stake in shares of Trevena during the first quarter valued at about $126,000. SG Americas Securities LLC increased its stake in shares of Trevena by 81.0% in the first quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 16,079 shares during the period. Rhumbline Advisers increased its stake in shares of Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,880 shares during the period. Finally, Weiss Multi Strategy Advisers LLC purchased a new stake in shares of Trevena during the first quarter valued at about $184,000. Institutional investors and hedge funds own 64.40% of the company’s stock.
Shares of Trevena, Inc. (NASDAQ:TRVN) opened at 2.41 on Friday. Trevena, Inc. has a 12 month low of $2.15 and a 12 month high of $8.00. The firm’s 50-day moving average is $2.55 and its 200 day moving average is $3.63. The firm’s market capitalization is $143.87 million.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). On average, equities research analysts anticipate that Trevena, Inc. will post ($1.40) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/12/trevena-inc-trvn-position-increased-by-bourgeon-capital-management-llc.html.
Several equities research analysts recently issued reports on TRVN shares. Needham & Company LLC raised their target price on shares of Trevena from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, May 15th. HC Wainwright reiterated a “buy” rating on shares of Trevena in a research note on Monday, May 8th. Roth Capital set a $9.00 target price on shares of Trevena and gave the company a “buy” rating in a research note on Saturday, May 6th. Oppenheimer Holdings, Inc. set a $10.00 target price on shares of Trevena and gave the company a “buy” rating in a research note on Thursday, May 4th. Finally, Aegis reiterated a “buy” rating and issued a $14.00 target price on shares of Trevena in a research note on Monday, April 17th. One equities research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.56.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding TRVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevena, Inc. (NASDAQ:TRVN).
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.